Answers are grounded in this paper and cite their sources.
Introduction. The SARS-CoV-2 virus is a highly variable pathogen accounted for by random mutations leading to the emergence of new genetic variants. Natural selection of SARS-CoV-2 variants is, among other things, the result of population level immunity impact. To predict the effectiveness of counteracting COVID-19 spread, it is necessary to study a potential for human immunity pre-formed against current virus strains to resist SARS-CoV-2 variants of concern for assessing ability of new genetic variants to escape the neutralizing antibodies to previously circulating variants pressure. The aim of the study was to compare neutralizing antibody titers in 2020 and 2023 COVID-19 convalescent patients to SARS-CoV-2 B.1.1 and JN.1 genetic variants strains. Materials and methods. Blood sera from 76 and 68 convalescent subjects, respectively, for 2020- and 2023-years samples were collected and stored at –70°C until used. The antibody titer was measured by neutralizing virus cytopathic effect in sensitive monolayer cell culture using test serum. The neutralizing activity of the sera was analyzed for two variants of SARS-CoV-2 VOC, Wuhan and Omicron. The statistical significance of the difference in antibody titers was assessed using the F-test; the difference was considered significant at p 0.01. Results. The differences in neutralizing titer levels were significant between all four samples: 2020 sera against JN.1, 2023 sera against JN.1, 2020 sera against B.1.1, and 2023 sera against B.1.1. Conclusion. Antigenic changes allow the current JN.1 variant to evade the effects of neutralizing antibodies developed against strains of previous genetic variants in some cases. The 2023 samples showed higher antibody titers in neutralizing strains of the old genetic variant B.1.1 due to repeated stimulation during vaccinations and reinfection. Spontaneous mutations being not crucial did not lead to changes in antigenic determinants critical for virus neutralization. Repeated contacts with altered genetic variants of SARS-CoV-2 increased protection against its parental wild type.
No takes yet. Share an insight, caveat, or question.
Pyankov et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: